相关实验视频

Updated: Jan 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

帕拉普托斯风景揭示了骨髓瘤中不同的预后和免疫微环境:对关键调节器TNK2的实验验证

Lei Zhou¹, Yong Tang¹, Changwei Chen¹

¹Department of Orthopedics, The Affiliated People's Hospital of Ningbo University, 251 East Baizhang Road, Ningbo City, Zhejiang Province, China.

European journal of pharmacology

|October 30, 2025

概括

这项研究确定了骨髓瘤 (OS) 中关键的亡相关基因 (PRG),并将它们与患者的生存和免疫反应联系起来. 增加TNK2表达对OS进展至关重要,并可能提供新的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物信息学是一种生物信息学.

背景情况:

骨髓瘤 (OS) 是一种具有复杂分子驱动力的侵袭性骨癌.
由于潜在的分子异质性,OS患者的治疗结果有很大差异.

研究的目的:

在OS中调查与亡相关的基因 (PRGs) 的景观.
评估PRG的预后价值及其与瘤免疫微环境的关联.
确定OS的新型治疗点.

主要方法:

在OS患者队列中对PRG进行生物信息分析 (TARGET和GSE21257).
达成共识的聚类用于分子亚型和LASSO-Cox回归风险评分的发展.
免疫分析,途径丰富分析,单细胞RNA测序和功能分析.

主要成果:

确定了60个PRG,共识聚类揭示了具有显著生存差异的独特分子亚型.
基于PRG的风险评分有效地将患者分为不同免疫细胞透的高风险和低风险组.
高风险的OS患者表现出抑制的免疫细胞活性和激活的WNT/BETA-CATENIN,TGF-BETA和KRAS通路.
恶性细胞中TNK2表达的升高与OS增殖,活力和迁移以及亡调节有关.

结论:

在OS预后和免疫微环境调制中,PRG起着至关重要的作用.
独特的OS分子亚型的特点是特定的信号通路活动和免疫特征.
TNK2是OS病变发生的关键驱动因素,是个性化治疗策略的潜在目标.

关键词:

骨质肉瘤骨质肉瘤是什么帕拉普托西斯 (Paraptosis) 是一种在分析中,分析.在TARGET上,你会看到TARGET.这就是TNK2的特征.

更多相关视频

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...